Cerebrolysin
Also known as: Porcine brain peptide preparation · FPF-1070
A complex mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue, studied extensively in cognitive decline and post-stroke recovery research.
- Category
- Neuroprotection
- Half-life
- Multiple components with varied pharmacokinetics
Section 1
Overview
Cerebrolysin is not a single peptide but a standardised preparation of low-molecular-weight neuropeptides and free amino acids derived from enzymatic digestion of porcine brain tissue. It has been used as a prescription parenteral neurotrophic preparation for several decades in many jurisdictions for indications including stroke recovery, dementia, and traumatic brain injury.
The preparation contains active fragments that mimic the action of endogenous neurotrophic factors such as BDNF, NGF, and GDNF, producing pleiotropic neuroprotective and neurotrophic effects in published research.
Because Cerebrolysin is a complex biological preparation rather than a single chemical entity, much of the published research is clinical and outcome-focused rather than mechanistically reductive — though substantial mechanistic work has been done in cell-culture and animal models.
Section 2
Discovery & History
- Developed in the 1950s and has been in continuous clinical use in various jurisdictions since the late 20th century.
- Manufactured by enzymatic digestion of purified porcine brain protein, yielding a standardised peptide-amino-acid mixture.
- Subject to a substantial body of clinical trial work in vascular dementia, Alzheimer's disease, stroke, and traumatic brain injury — primarily from European and Asian research centres.
- Not approved by the UK MHRA or the US FDA.
Section 3
Mechanism of Action
- 1Mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF) through bioactive low-molecular-weight peptide fragments.
- 2Promotes neuronal survival under ischaemic and oxidative stress in cell-culture and animal models.
- 3Modulates amyloid-beta processing in research models of Alzheimer-type pathology.
- 4Anti-apoptotic effects via stabilisation of the mitochondrial apoptotic pathway.
- 5Modulation of microglial activation and reduction of neuroinflammatory mediators in ischaemic injury models.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Improvement in cognitive scores in published vascular-dementia trials.
- 2Faster recovery of neurological function after ischaemic stroke in randomised research.
- 3Reduction in apoptotic neuronal loss in head-injury research models.
- 4Long history of clinical use in many jurisdictions, providing extensive real-world data.
- 5Pleiotropic mechanism — multiple bioactive components rather than a single target.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Intravenous infusion (clinical use in approving jurisdictions) | Trial doses typically 10–50 mL of standardised preparation | Daily during a treatment cycle | Typical clinical cycles run 10–20 days, sometimes repeated |
Note: Not approved or prescribed in the UK; this information is provided for educational reference only.
Section 6
Administration Routes
- Intravenous infusion in clinical use.
- Intramuscular in some protocols.
- Oral administration is not used: the preparation requires parenteral delivery to be effective.
Section 7
Safety Profile
Commonly reported
- · Transient sensations of warmth or flushing during infusion (reported in clinical use)
- · Mild injection-site reactions in IM administration
- · Headache or dizziness in a minority of subjects
Rare / theoretical
- · Hypersensitivity reactions to the porcine-derived preparation
- · Theoretical infectious-disease considerations associated with animal-derived biologics (managed in licensed manufacture by extensive purification and viral inactivation)
Contraindications
- · Not licensed in the United Kingdom
- · Status epilepticus (per labelling in approving jurisdictions)
- · Severe renal impairment (per labelling)
- · Known hypersensitivity to porcine-derived proteins
Section 8
UK & EU Regulatory Context
United Kingdom
Not licensed as a medicine in the UK. Used clinically in many other jurisdictions including parts of Asia and Eastern Europe.
European Union
Approved as a medicinal product in several EU and Eastern European countries; not approved in others. No centralised EMA authorisation.
Section 9
Clinical Studies Summary
Cerebrolysin in vascular dementia — meta-analysis
Pooled analysis of randomised trials reporting cognitive improvement versus placebo in vascular dementia cohorts.
Cerebrolysin in acute ischaemic stroke
Multicentre randomised study reporting accelerated neurological recovery in subjects receiving Cerebrolysin adjunct therapy.
Mechanistic dissection of Cerebrolysin's anti-amyloid effects
Animal-model work reporting reduced amyloid-beta accumulation and improved spatial-learning performance.
Section 10
Frequently Asked Questions
Section 11
Sourcing for Laboratory Research
Sourcing Cerebrolysin for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Cerebrolysin from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.